SMMT 23.76 Summit Therapeutics Inc.
| Range: | 1.64-33.89 | Vol Avg: | 4985926 | Last Div: | 0 | Changes: | 1.34 |
| Beta: | -0.97 | Cap: | 14.45B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 05 2015 | Empoloyees: | 105 | ||
| CUSIP: | 86627T108 | CIK: | 0001599298 | ISIN: | US86627T1088 | Country: | US |
| CEO: | Mr. Robert W. Duggan | Website: | https://www.summittxinc.com | ||||
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Stock Details
Positive 0.20
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks....
https://www.fool.com/investing/2024/10/15/up-700-this-year-is-it-too-late-to-invest-in-this/·Tue Oct 15 2024
Neutral 0.06
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel....
fool.com·Sat Oct 05 2024
Neutral 0.00
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers....
fool.com·Fri Oct 04 2024
Neutral 0.00
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing....
fool.com·Thu Oct 03 2024
Positive 0.40
Has Summit Therapeutics Stock Already Peaked?
Summit Therapeutics stock is up a remarkable 700% this year....
fool.com·Wed Oct 02 2024
Positive 0.30
Is Summit Therapeutics Stock a Buy?
Summit Therapeutics is having a great year, and it could realize revenue soon. Its partner...
fool.com·Mon Sep 30 2024
Neutral -0.10
Why Summit Therapeutics Skyrocketed 123% This Week
Summit's Ivonescimab bested Keytruda in a phase 3 trial for lung cancer patients with the ...
fool.com·Fri Sep 13 2024
Positive 0.21
Why Summit Therapeutics Stock Is Soaring Again Today
Several accredited investors entered an agreement to buy roughly $235 million of Summit Th...
fool.com·Thu Sep 12 2024
Positive 0.12
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics Inc. NASDAQ: SMMT has seen a meteoric rise this month, surging over 10...
marketbeat.com·Thu Sep 12 2024
Negative -0.30
Is Summit Therapeutics a Buy Now?
Ivonescimab is a bispecific antibody that targets PD-1 and VEGF to treat lung cancer. In a...
fool.com·Tue Sep 10 2024
Positive 0.15
Why Summit Therapeutics Rocketed Over 60% Today
Summit's lung cancer treatment Ivonescimab outperformed Merck's Keytruda in a Phase III tr...
fool.com·Mon Sep 09 2024
Positive 0.25
Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation
Summit's and Akeso's ivonescimab outperformed Merck's Keytruda in a phase 3 trial for firs...
seekingalpha.com·Mon Sep 09 2024
Positive 0.10
Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today
Shares of Summit Therapeutics (SMMT) skyrocketed Monday, rising to an all-time high after ...
investopedia.com·Mon Sep 09 2024
Positive 0.25
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda....
investors.com·Mon Sep 09 2024
Neutral 0.10
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we,"...
businesswire.com·Sun Sep 08 2024
Новини маркету
Найкращі для покупки
Контент, наданий на цьому сайті, призначений лише для інформаційних цілей і не є фінансовою, інвестиційною чи професійною порадою. Ми не є зареєстрованими інвестиційними радниками або фінансовими планерами, і ми не надаємо рекомендацій чи порад щодо купівлі, продажу або утримання будь-яких конкретних акцій або цінних паперів. Будь-які інвестиційні рішення слід приймати на основі власних досліджень та консультацій з кваліфікованим фінансовим фахівцем. Ми не несемо відповідальності за будь-які фінансові втрати чи збитки, понесені внаслідок покладання на інформацію, надану на цьому сайті. Будь ласка, інвестуйте відповідально та звертайтесь за професійною порадою, коли це потрібно.
• Створено StackThrow